Fc variants with optimized Fc receptor binding properties

Details for Australian Patent Application No. 2006299429 (hide)

Owner Xencor, Inc

Inventors Carmichael, David F.; Moore, Gregory L.; Lazar, Gregory Alan; Richards, John O.; Karki, Sher Bahadur; Desjarlais, John R.

Agent Davies Collison Cave

Pub. Number AU-B-2006299429

PCT Pub. Number WO2007/041635

Priority 60/750,699 15.12.05 US; 60/723,294 03.10.05 US; 11/396,495 31.03.06 US; 60/774,358 17.02.06 US; 60/745,078 18.04.06 US; 60/779,961 06.03.06 US; 60/739,696 23.11.05 US; 60/723,335 03.10.05 US; 60/741,966 02.12.05 US

Filing date 3 October 2006

Wipo publication date 12 April 2007

Acceptance publication date 23 February 2012

International Classifications

C07K 16/00 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C07K 16/30 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Event Publications

24 April 2008 PCT application entered the National Phase

  PCT publication WO2007/041635 Priority application(s): WO2007/041635

23 February 2012 Application Accepted

  Published as AU-B-2006299429

21 June 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006299431-Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2 -yl)-piperidine-2,6-dione for treatment of certain leukemias

2006299428-Pyrimidine amide compounds as PGDS inhibitors